Table 3.
Production of CXCL10 and IFN-β in the absence and presence of poly(I:C) in PBMCs from HC cases and pwMS.
| Cytokine/Chemokine | Basal | Treatment with Poly(I:C) | Mean Difference after Treatment (Fold Change) |
|---|---|---|---|
| CXCL10 (pg/mL) | |||
| HC | 74.6 ± 13.3 | 587.6 ± 94.1 *** | 513.0 (7.9) |
| MS | 28.0 ± 7.5 | 289.6 ± 71.6 # | 261.6 (10.3) |
| IFN-β (pg/mL) | |||
| HC | 0.68 ± 0.22 | 2.46 ± 0.39 * | 1.78 (3.6) |
| MS | 0.72 ± 0.18 | 3.39 ± 0.68 +++ | 2.67 (4.7) |
The table includes mean CXCL10 and IFN-β values in culture media ± SEM. * p < 0.05, *** p < 0.001 versus basal CXCL10 and IFN-β production in PBMCs from HC cases. # p < 0.05 versus CXCL10 production in poly(I:C)-treated PBMCs from HC cases. +++ p < 0.001 versus basal IFN-β production in PBMCs from MS cases. HC: Healthy control; MS: Multiple sclerosis. Values are available for 20–24 HC cases and 14–15 pwMS. Statistical analysis: two-way ANOVA.